What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in miscarriage (moderate certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 1.03 [0.75, 1.41]
  10 studies · 1680 participants
  Moderate

Intervention not reported

The intervention may leads to lower ongoing pregnancy (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.68 [0.51, 0.9]
  5 studies · 1121 participants
  Low

Intervention not reported

The intervention probably leads to lower clinical pregnancy (moderate certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.56 [0.42, 0.73]
  5 studies · 1131 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in cumulative live birth (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 1.05 [0.66, 1.66]
  1 study · 396 participants
  Low

Intervention not reported

The intervention showed no clear difference in live birth rate after the first embryo transfer (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 1.1 [0.68, 1.79]
  1 study · 396 participants
  Low

Intervention not reported

The intervention may leads to lower miscarriage (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.45 [0.23, 0.88]
  1 study · 396 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in clinical pregnancy (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.77 [0.5, 1.16]
  1 study · 396 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in cumulative live birth (low certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.59 [0.35, 1.01]
  1 study · 408 participants
  Low

Intervention not reported

The intervention probably leads to lower live birth rate after the first embryo transfer (moderate certainty).

• Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation 2020 · Cochrane Headline outcomes only
  OR 0.62 [0.43, 0.91]
  10 studies · 1680 participants
  Moderate

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes live birth rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  RR 0.48 [0.26, 0.87]
  1 study · 147 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes complication rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  Peto OR 1.23 [0.37, 4.14]
  3 studies · 318 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes clinical pregnancy rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  RR 1.13 [0.91, 1.41]
  6 studies · 552 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes multiple pregnancy rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  Peto OR 0.14 [0.04, 0.56]
  2 studies · 208 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

It is very uncertain whether long‐term GnRH agonist therapy changes miscarriage rate compared with no additional therapy (very low certainty).

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  Peto OR 0.45 [0.1, 2]
  2 studies · 208 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 385 participants
  Very low

Long‐term GnRH agonist therapy vs no additional therapy

• Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 267 participants
  Very low

Glucocorticoid supplementation vs placebo

Glucocorticoid supplementation showed no clear difference in live birth rate compared with placebo (low certainty).

• Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI 2017 · Cochrane Headline outcomes only
  OR 1.08 [0.45, 2.58]
  2 studies · 212 participants
  Low